These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 9741652

  • 1. Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801.
    Ninan I, Kulkarni SK.
    Indian J Physiol Pharmacol; 1998 Jul; 42(3):375-82. PubMed ID: 9741652
    [Abstract] [Full Text] [Related]

  • 2. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
    Gaisler-Salomon I, Weiner I.
    Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
    [Abstract] [Full Text] [Related]

  • 3. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats.
    Gattaz WF, Schummer B, Behrens S.
    J Neural Transm Gen Sect; 1994 Apr; 96(3):227-32. PubMed ID: 7826573
    [Abstract] [Full Text] [Related]

  • 4. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ, Brocco M, Rivet JM, Audinot V, Newman-Tancredi A, Maiofiss L, Queriaux S, Despaux N, Peglion JL, Dekeyne A.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [Abstract] [Full Text] [Related]

  • 5. Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine.
    Scorza MC, Meikle MN, Hill XL, Richeri A, Lorenzo D, Artigas F.
    Int J Neuropsychopharmacol; 2008 Jun; 11(4):519-32. PubMed ID: 18248688
    [Abstract] [Full Text] [Related]

  • 6. Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions.
    Arif M, Chikuma T, Ahmed MM, Yoshida S, Kato T.
    Neurosci Res; 2007 Feb; 57(2):248-58. PubMed ID: 17141345
    [Abstract] [Full Text] [Related]

  • 7. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G, Rogóz Z, Wieczorek A.
    Pol J Pharmacol; 1997 Feb; 49(1):5-15. PubMed ID: 9431546
    [Abstract] [Full Text] [Related]

  • 8. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
    Karasawa J, Hashimoto K, Chaki S.
    Behav Brain Res; 2008 Jan 10; 186(1):78-83. PubMed ID: 17854919
    [Abstract] [Full Text] [Related]

  • 9. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade.
    Levin ED, Petro A, Caldwell DP.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May 10; 29(4):581-6. PubMed ID: 15866361
    [Abstract] [Full Text] [Related]

  • 10. Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.
    Deshpande C, Dhir A, Kulkarni SK.
    Pharmacology; 2006 May 10; 77(1):38-45. PubMed ID: 16569938
    [Abstract] [Full Text] [Related]

  • 11. Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
    Fredriksson A, Archer T.
    Amino Acids; 2002 May 10; 23(1-3):111-32. PubMed ID: 12373526
    [Abstract] [Full Text] [Related]

  • 12. Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine.
    O'Neill MF, Hicks CA, Shaw G, Parameswaran T, Cardwell GP, O'Neill MJ.
    J Pharmacol Exp Ther; 1998 Dec 10; 287(3):839-46. PubMed ID: 9864262
    [Abstract] [Full Text] [Related]

  • 13. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
    Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y.
    Eur J Pharmacol; 2007 Oct 31; 572(2-3):160-70. PubMed ID: 17662268
    [Abstract] [Full Text] [Related]

  • 14. Effect of GNTI, a kappa opioid receptor antagonist, on MK-801-induced hyperlocomotion and stereotypy in mice.
    Qi CT, Zou H, Zhang CH, Xie QL, Jin ML, Yu L.
    Acta Pharmacol Sin; 2006 Nov 31; 27(11):1401-8. PubMed ID: 17049114
    [Abstract] [Full Text] [Related]

  • 15. Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio).
    Seibt KJ, Oliveira Rda L, Zimmermann FF, Capiotti KM, Bogo MR, Ghisleni G, Bonan CD.
    Behav Brain Res; 2010 Dec 25; 214(2):417-22. PubMed ID: 20600350
    [Abstract] [Full Text] [Related]

  • 16. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats.
    Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A.
    Behav Brain Res; 2008 Jan 25; 186(2):197-207. PubMed ID: 17881065
    [Abstract] [Full Text] [Related]

  • 17. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats.
    Hoffman DC.
    J Neural Transm Gen Sect; 1992 Jan 25; 89(1-2):1-10. PubMed ID: 1358122
    [Abstract] [Full Text] [Related]

  • 18. MK-801-induced stereotypy and its antagonism by neuroleptic drugs.
    Tiedtke PI, Bischoff C, Schmidt WJ.
    J Neural Transm Gen Sect; 1990 Jan 25; 81(3):173-82. PubMed ID: 1975747
    [Abstract] [Full Text] [Related]

  • 19. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating.
    Bubeníková V, Votava M, Horácek J, Pálenícek T, Dockery C.
    Pharmacol Biochem Behav; 2005 Apr 25; 80(4):591-6. PubMed ID: 15820528
    [Abstract] [Full Text] [Related]

  • 20. Clozapine but not haloperidol suppresses the changes in the levels of neuropeptides in MK-801-treated rat brain regions.
    Arif M, Ahmed MM, Kumabe Y, Hoshino H, Chikuma T, Kato T.
    Neurochem Int; 2006 Aug 25; 49(3):304-11. PubMed ID: 16567023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.